New Analysis of Soloist-WHF Trial Underscores Sotagliflozin's Effect on Reducing Recurrent Heart Failure Events
New analysis adds to growing body of evidence in support of the use of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, in the treatment of heart failureย
United States Craig Granowitz Bertram Pitt Heart Failure Society Of America Science Session Of The American Heart Association Committee For The Phase
Source: dicardiology.com